You Shouldn't Ignore Gilead's Idelalisib
Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.
Investing in Counteracting Biological and Chemical Agents
Biological and chemical agents are a lethal scourge of war, but Emergent Biosciences is developing countermeasures to a wide range of such agents.